Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $122.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-14
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $122.00K, a 165.22% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $131.00K, a 184.78% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $896.00K, a 1237.31% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $37.00K, a 95.16% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $1.02M, a 32.57% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $1.52M, a 27.62% increase from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $1.19M, a 57.59% decline from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $2.81M, a 153.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $122.00K 10-Q · filed 2026-08-14 | $253.00K 10-Q · filed 2026-08-14 | $1.15M derived: sum of 3 quarters · filed 2026-08-14 | $1.19M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $131.00K 10-Q · filed 2026-05-15 | $1.03M derived: sum of 2 quarters · filed 2026-05-15 | $1.06M derived: sum of 3 quarters · filed 2026-05-15 | $1.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $896.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $933.00K derived: sum of 2 quarters · filed 2026-03-26 | $979.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.02M 10-K · filed 2026-03-26 |
| 2025-09-30 | $37.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $83.00K derived: sum of 2 quarters · filed 2026-08-14 | $129.00K 10-Q · filed 2025-11-14 | $196.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $46.00K 10-Q · filed 2026-08-14 | $92.00K 10-Q · filed 2026-08-14 | $159.00K derived: sum of 3 quarters · filed 2026-08-14 | $923.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $46.00K 10-Q · filed 2026-05-15 | $113.00K derived: sum of 2 quarters · filed 2026-05-15 | $877.00K derived: sum of 3 quarters · filed 2026-05-15 | $1.34M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $831.00K derived: sum of 2 quarters · filed 2026-03-26 | $1.29M derived: sum of 3 quarters · filed 2026-03-26 | $1.52M 10-K · filed 2026-03-26 |
| 2024-09-30 | $764.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.23M derived: sum of 2 quarters · filed 2025-11-14 | $1.45M 10-Q · filed 2025-11-14 | $1.61M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $689.00K 10-Q · filed 2025-08-14 | $847.00K derived: sum of 3 quarters · filed 2025-08-14 | $1.08M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $228.00K 10-Q · filed 2025-05-15 | $386.00K derived: sum of 2 quarters · filed 2025-05-15 | $623.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.01M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $395.00K derived: sum of 2 quarters · filed 2025-04-07 | $786.00K derived: sum of 3 quarters · filed 2025-04-07 | $1.19M 10-K · filed 2025-04-07 |
| 2023-09-30 | $237.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $628.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.03M 10-Q · filed 2024-11-14 | $1.42M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $796.00K 10-Q · filed 2024-08-14 | $1.18M derived: sum of 3 quarters · filed 2024-08-14 | $1.60M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $405.00K 10-Q · filed 2024-05-15 | $793.00K derived: sum of 2 quarters · filed 2024-05-15 | $1.21M derived: sum of 3 quarters · filed 2024-05-15 | $3.03M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $805.00K derived: sum of 2 quarters · filed 2024-04-15 | $2.62M derived: sum of 3 quarters · filed 2024-04-15 | $2.81M 10-K · filed 2024-04-15 |
| 2022-09-30 | $417.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-13 | $2.23M derived: sum of 2 quarters · filed 2023-10-13 | $2.42M 10-Q · filed 2023-10-13 | $2.61M derived: sum of 4 quarters · filed 2023-10-13 |
| 2022-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $2.00M 10-Q · filed 2023-08-11 | $2.19M derived: sum of 3 quarters · filed 2023-08-11 | $2.40M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $186.00K 10-Q · filed 2023-05-08 | $374.00K derived: sum of 2 quarters · filed 2023-05-08 | $584.00K derived: sum of 3 quarters · filed 2023-05-08 | $916.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $398.00K derived: sum of 2 quarters · filed 2023-03-20 | $730.00K derived: sum of 3 quarters · filed 2023-03-20 | $1.11M 10-K · filed 2023-03-20 |
| 2021-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $542.00K derived: sum of 2 quarters · filed 2022-11-01 | $918.00K 10-Q · filed 2022-11-01 | $1.32M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $332.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $708.00K 10-Q · filed 2022-08-15 | $1.11M derived: sum of 3 quarters · filed 2022-08-15 | $1.63M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $376.00K 10-Q · filed 2022-05-05 | $781.00K derived: sum of 2 quarters · filed 2022-05-05 | $1.30M derived: sum of 3 quarters · filed 2022-05-05 | $2.03M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $926.00K derived: sum of 2 quarters · filed 2022-03-28 | $1.65M derived: sum of 3 quarters · filed 2022-03-28 | $2.10M 10-K · filed 2022-03-28 |
| 2020-09-30 | $521.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.25M derived: sum of 2 quarters · filed 2021-11-12 | $1.69M 10-Q · filed 2021-11-12 | $2.09M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $726.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.17M 10-Q · filed 2021-08-11 | $1.57M derived: sum of 3 quarters · filed 2021-08-11 | $2.27M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $447.00K 10-Q · filed 2021-05-11 | $847.00K derived: sum of 2 quarters · filed 2021-05-11 | $1.54M derived: sum of 3 quarters · filed 2021-05-11 | $2.17M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $1.09M derived: sum of 2 quarters · filed 2021-03-24 | $1.73M derived: sum of 3 quarters · filed 2021-03-24 | $2.24M 10-K · filed 2021-03-24 |
| 2019-09-30 | $694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.33M derived: sum of 2 quarters · filed 2020-11-12 | $1.84M 10-Q · filed 2020-11-12 | $2.09M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $633.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.14M 10-Q · filed 2020-08-05 | $1.40M derived: sum of 3 quarters · filed 2020-08-05 | $2.22M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $509.00K 10-Q · filed 2020-05-11 | $765.00K derived: sum of 2 quarters · filed 2020-05-11 | $1.59M derived: sum of 3 quarters · filed 2020-05-11 | $2.88M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $256.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $1.08M derived: sum of 2 quarters · filed 2020-03-30 | $2.38M derived: sum of 3 quarters · filed 2020-03-30 | $2.89M 10-K · filed 2020-03-30 |
| 2018-09-30 | $821.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $2.12M derived: sum of 2 quarters · filed 2019-11-07 | $2.63M 10-Q · filed 2019-11-07 | $3.09M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.81M 10-Q · filed 2019-08-06 | $2.27M derived: sum of 3 quarters · filed 2019-08-06 | $2.67M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $514.00K 10-Q · filed 2019-05-08 | $972.00K derived: sum of 2 quarters · filed 2019-05-08 | $1.37M derived: sum of 3 quarters · filed 2019-05-08 | $1.62M derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $856.00K derived: sum of 2 quarters · filed 2019-03-29 | $1.11M derived: sum of 3 quarters · filed 2019-03-29 | $1.27M 10-K · filed 2019-03-29 |
| 2017-09-30 | $398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $652.00K derived: sum of 2 quarters · filed 2018-11-07 | $810.00K 10-Q · filed 2018-11-07 | $876.00K derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $412.00K 10-Q · filed 2018-08-07 | $478.00K derived: sum of 3 quarters · filed 2018-08-07 | $651.00K derived: sum of 4 quarters · filed 2018-08-07 |
| 2017-03-31 | $158.00K 10-Q · filed 2018-05-09 | $224.00K derived: sum of 2 quarters · filed 2018-05-09 | $397.00K derived: sum of 3 quarters · filed 2018-05-09 | |
| 2016-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $239.00K derived: sum of 2 quarters · filed 2018-04-02 | $784.00K 10-K · filed 2018-04-02 | |
| 2016-09-30 | $173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $718.00K 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $545.00K 10-Q · filed 2017-08-10 | |||
| 2015-12-31 | $442.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |